Edition:
United States

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

49.08USD
19 Jul 2018
Change (% chg)

$1.20 (+2.51%)
Prev Close
$47.88
Open
$47.77
Day's High
$49.61
Day's Low
$47.18
Volume
625,179
Avg. Vol
1,529,332
52-wk High
$111.36
52-wk Low
$17.52

Select another date:

Sun, Jun 3 2018

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

BRIEF-Nektar Therapeutics Reports Q1 Loss Per Share $0.60

* Q1 EARNINGS PER SHARE VIEW $-0.54 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Select another date: